Tax cut won’t mitigate high prices for cancer, rare diseases medicines, say patient advocacy groups
Photo used for illustration purpose only. | Photo Credit: Getty Images/iStockphoto The recent Union Budget announcement provided custom duty waiver to 36 exorbitantly priced cancer and rare diseases drugs, but patient advocacy groups highlight that the tax cut doesn’t tackle the underlying problem of high prices due to patent monopolies that block local production and offer very little to ease…
